# Dermatomyositis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/dermatomyositis

> No upcoming FDA catalysts in dermatomyositis; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for dermatomyositis?

No upcoming FDA catalysts in dermatomyositis; 3 past events are recorded. SEC Form 8-K: "On August 27, 2026, Roivant Sciences Ltd. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration had approved the New Drug" [Calendar and source filings](https://sec-api.dev/indications/dermatomyositis)

Source: SEC Form 8-K, accession 0001140361-26-034735, https://www.sec.gov/Archives/edgar/data/1635088/000114036126034735/ef20081229_8k.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/indications/dermatomyositis#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 13, 2025 | [Cadefrecitinib primary completion](https://sec-api.dev/pdufa/cadefrecitinib) | LKFT | Dermatomyositis | completed | "NCT05695950 (A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Lakefront Biotherapeutics NV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05695950)) |
| December 18, 2025 | [GLPG3667 topline data readout](https://sec-api.dev/pdufa/glpg3667) | LKFT | dermatomyositis | completed, met | "corticosteroid, OLE: open-label extension, QD: once daily, R: randomization On December 18, 2025, we announced topline results from the GALARISSO study, which are summarized below: The GALARISSO DM study met its primary endpoint, showing that" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1421876/000119312526130447/d54917dex993.htm)) |
| August 27, 2026 | [LISRAYA™ (brepocitinib) FDA approval](https://sec-api.dev/pdufa/brepocitinib) | ROIV | Dermatomyositis | completed, approved | "On August 27, 2026, Roivant Sciences Ltd. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration had approved the New Drug" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1635088/000114036126034735/ef20081229_8k.htm)) |

## Drugs

- [Cadefrecitinib](https://sec-api.dev/pdufa/cadefrecitinib) (LKFT)
- [GLPG3667](https://sec-api.dev/pdufa/glpg3667) (LKFT)
- [LISRAYA™ (brepocitinib)](https://sec-api.dev/pdufa/brepocitinib) (ROIV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/dermatomyositis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Dermatomyositis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/dermatomyositis

```bibtex
@misc{secapidev_indications_dermatomyositis_20261116,
  title        = {Dermatomyositis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/dermatomyositis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_dermatomyositis_20261116","title":"Dermatomyositis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/dermatomyositis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
